Drug class in one race
CD20 drugs for Multiple Sclerosis
9 tracked CD20 drugs in the Multiple Sclerosis race. The class explanation lives on the CD20 page; the full indication pipeline across every mechanism is on the Multiple Sclerosis page.
4 approved / phase 45 Phase 3
Head-to-head evidence: ABP 692 vs BCD-132 · ABP 692 vs Divozilimab · ABP 692 vs Ocrelizumab · ABP 692 vs Ofatumumab · ABP 692 vs Ublituximab · BCD-132 vs BCD-281